10 Best Performing Biotech Stocks in 2024
The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and government assistance.
Catalyst Pharmaceuticals Inc. (CPRX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deerfield Management James E. Flynn | 6,229,634 | $123,845,124 | -32% | 1.85% |
| 2. | Renaissance Technologies Jim Simons | 2,526,016 | $50,217,198 | +17% | 0.07% |
| 3. | Royce & Associates Chuck Royce | 2,021,105 | $40,179,567 | -7% | 0.36% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 860,934 | $17,115,368 | -30% | 0.02% |
| 5. | Millennium Management Israel Englander | 559,767 | $11,128,168 | +332% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.99 | 7,000 | Director | 560,376 | 2020-09-30 | Filing | |
| $2.97 | 15,000 | Officer, Director | 4,787,693 | 2020-09-30 | Filing | |
| $4.70 | 10,000 | Director | 553,376 | 2019-10-11 | Filing | |
| $4.89 | 10,000 | Officer, Director | 4,772,693 | 2019-10-03 | Filing | |
| $3.23 | 25,000 | Officer, Director | 4,762,693 | 2019-06-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.93 | 50,000 | Officer | 686,996 | 2024-12-10 | Filing | |
| $22.67 | 3,369 | Officer | 51,391 | 2024-11-27 | Filing | |
| $22.74 | 8,631 | Officer | 54,760 | 2024-11-27 | Filing | |
| $22.00 | 17,500 | Director | 0 | 2024-11-27 | Filing | |
| $21.58 | 3,956 | Officer | 171,177 | 2024-11-26 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,822,299 | $265,972,852 | 0% | |
| 2. | 7,120,417 | $119,694,211 | 0% | |
| 3. | 6,787,332 | $114,095,051 | 0% | |
| 4. | 2,601,797 | $43,737,912 | 0.01% | |
| 5. | 2,200,225 | $36,990,038 | 0% |
News See All
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Kris and I will be your conference operator today.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Catalyst Pharmaceuticals' Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Catalyst Pharmaceuticals' First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Jim Cramer's 10 Favorite Healthcare Stock Picks in 2024
In this article, we will take a detailed look at Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024. For a quick overview of such stocks, read our article Jim Cramer’s 5 Favorite Healthcare...
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2023 Earnings Call Transcript
Operator: Hello, and welcome to the Catalyst Pharmaceuticals Inc. Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2023 Earnings Call Transcript
Operator: Hello, and welcome to the Catalyst Pharmaceuticals Third Quarter 2023 Financial Results Conference Call and Webcast [Operator Instructions]. As a reminder, this conference is being recorded.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2023 Earnings Call Transcript
Operator: Hello, and welcome to the Catalyst Pharmaceutical Second Quarter 2023 Financial Results Conference Call and Webcast.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2023 Earnings Call Transcript
Operator: Greetings and welcome to the Catalyst Pharmaceuticals first quarter 2023 financial results conference call. At this time, all participants are in a listen-only mode.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2022 Earnings Call Transcript
Operator: Greetings and welcome to the Catalyst Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time all participants are in a listen-only mode.
Billionaire Hedge Funds
